Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 6/20 | 0.34 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511027 | 0.87 | ATR (0.42) | CHEK1CNR2ATRNAMPT | |
| SCHEMBL6514701 | 0.83 | CHEK1 (0.36) | CHEK1CNR2ATRKRASHTR2C | |
| SCHEMBL6507186 | 0.83 | HTR2C (0.41) | CHEK1CNR2ATRKRASHTR2C | |
| SCHEMBL6514903 | 0.82 | HTR2C (0.37) | CHEK1CNR2ATRKRASHTR2C | |
| SCHEMBL6510585 | 0.82 | ATR (0.37) | CHEK1CNR2ATRKRASHTR2C | |
| SCHEMBL6517473 | 0.82 | ATR (0.42) | CNR2ATR | |
| SCHEMBL6512818 | 0.81 | P2RX3 (0.40) | CHEK1CNR2KRASP2RX3HTR2C | |
| SCHEMBL6508960 | 0.81 | ATR (0.41) | CHEK1CNR2ATRNAMPT | |
| SCHEMBL6521803 | 0.79 | PLK1 (0.44) | CNR2ATR | |
| SCHEMBL6508889 | 0.79 | ATR (0.42) | CNR2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885CNR2 3139/4885ATR 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.